Virios therapeutics' announces dosing of first patient in imc-2 long-covid treatment trial

Atlanta--(business wire)---- $viri #biotech--virios therapeutics, inc. (nasdaq: viri), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“fm”), today announced commencement of enrollment in its exploratory long-covid trial. this study is supported via an unrestricted investigational grant to the bateman horne center, a non-profit, interdisciplinary center of excellence advancing the diagnosis and tr
VIRI Ratings Summary
VIRI Quant Ranking